Agenus Inc. (NASDAQ:AGEN) Receives Consensus Recommendation of “Hold” from Analysts

Agenus Inc. (NASDAQ:AGEN) has received a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $8.75.

A number of research analysts have issued reports on the company. Robert W. Baird decreased their price target on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, March 12th. HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Tuesday, March 18th. Finally, StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Friday, March 21st.

Agenus Price Performance

NASDAQ:AGEN opened at $2.08 on Friday. The company’s fifty day moving average price is $2.21 and its 200-day moving average price is $3.10. Agenus has a 1-year low of $1.38 and a 1-year high of $19.69. The firm has a market capitalization of $52.64 million, a P/E ratio of -0.19 and a beta of 1.58.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, topping the consensus estimate of ($2.36) by $0.32. The company had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million. Equities analysts anticipate that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. HighTower Advisors LLC boosted its position in Agenus by 46.1% during the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. State Street Corp grew its position in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares in the last quarter. Barclays PLC increased its holdings in shares of Agenus by 295.3% in the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 20,777 shares during the last quarter. Geode Capital Management LLC lifted its position in Agenus by 7.1% during the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock worth $2,648,000 after buying an additional 32,016 shares in the last quarter. Finally, Apollon Wealth Management LLC acquired a new position in Agenus during the fourth quarter worth $55,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.